By consolidating legacy buildings, Colorcon enhances environmental and production efficiencies at West Point, PA facility.
Excipient manufacturer Colorcon, Inc., has completed a multimillion-dollar expansion and renovation at its North America production facility in West Point, PA, to enhance the company’s supply chain robustness for products manufactured and delivered to oral solid dose manufacturers in North America, Central America, and Latin America.
The investment included the consolidation of multiple legacy buildings into a unified manufacturing campus, eliminating off-site warehousing, which will reduce and traffic and noise in the area, the company reported in a Dec. 18, 2019 press statement.
“The investment in our West Point, USA facility brings together expanded material warehousing and new best-in-class quality control laboratories to the existing production capabilities,” said Simon Tasker, president Americas region in the press statement. “This supports our future growth expectations, improves our environmental foot print and reduces supply lead times for our customers.”
“Colorcon’s West Point, Pennsylvania, site is one of seven film coating manufacturing sites strategically located around the world and is an important component in Colorcon’s Business Continuity Plan,” added Martti Hedman, Colorcon CEO in the press statement. “This multi-year investment helps Colorcon to further improve its service to the customers and is a good example of how Colorcon invests in new capacity ahead of demand.”
Source: Colorcon
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.